Compare Medtronic PLC (MDT) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs TKO Group Holdings Inc — how do they compare? Medtronic PLC trades at $87.9 (market cap $112.24B), while TKO Group Holdings Inc trades at $181.02 (market cap $13.28B). The key difference: Medtronic PLC is far larger — about 8.5× TKO Group Holdings Inc's market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and TKO Group Holdings Inc for 30 Days on average.
| MDT | TKO | |
|---|---|---|
Market Cap | $112.24B | $13.28B |
Volume | 105,663,236 | 857,653 |
Sector | Health | Media |
52-Week High | $105.35 | $224.96 |
52-Week Low | $73.75 | $175.58 |
Typical Hold Time | 63 Days | 30 Days |
Enterprise Value | $131.58B | $17.64B |
Dividend Yield | 3.28% | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $85.51, down 1.81% on the day, showing bearish technical signals despite strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters with Q3 2026 results pending, while maintaining robust profitability margins of 65% gross and 14% net. Recent news highlights the company's 49-year dividend growth streak and new product approvals, though technical indicators show selling pressure with the stock trading near support at $85.
MDT presents a compelling value opportunity with a 3.2% dividend yield and 14% upside to the $97.80 consensus target, though near-term technical weakness and increasing debt levels warrant caution. The company's consistent earnings beats and medical device market leadership support long-term growth, while regulatory approvals for new systems provide catalysts.
TKO trades at $178.64, up 1.24% on the day but near recent lows, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, missing EPS estimates but raising full-year guidance. Revenue growth is solid, with 2026 projected at $5.3B, though net margins remain thin at 4.33%. A quarterly dividend of $0.79 was declared for payment in September 2026.
The stock presents a contrast between strong analyst bullishness (89% buy rating, $227 consensus target) and current technical weakness. Upside hinges on execution of media rights monetization and live event growth, while risks include competitive pressures and margin sustainability. The valuation at a P/E of 63.73 demands high future earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
